Impact of dupilumab prescribing on utilization of medical and surgical therapies for chronic rhinosinusitis with nasal polyps

doi:10.1002/alr.23325

. 2024 Jul;14(7):1249-1252.

doi: 10.1002/alr.23325. Epub 2024 Jan 31.

Impact of dupilumab prescribing on utilization of medical and surgical therapies for chronic rhinosinusitis with nasal polyps

Christopher M Low^{1

2}, Allan R Wang^{1

3}, Michael Yong¹, Jayakar Nayak¹, Zara Patel¹, Peter H Hwang¹

Affiliations

¹ Division of Rhinology-Sinus and Skull Base Surgery, Department of Otolaryngology-Head and Neck Surgery, Stanford University School of Medicine, Stanford, California, USA.
² Ear, Nose and Throat Center, Park Ridge, Illinois, USA.
³ Department of Head and Neck Surgery, University of California Los Angeles, Los Angeles, California, USA.

PMID: 38297486
DOI: 10.1002/alr.23325

Impact of dupilumab prescribing on utilization of medical and surgical therapies for chronic rhinosinusitis with nasal polyps

Christopher M Low et al. Int Forum Allergy Rhinol. 2024 Jul.

. 2024 Jul;14(7):1249-1252.

doi: 10.1002/alr.23325. Epub 2024 Jan 31.

Authors

Christopher M Low^{1

2}, Allan R Wang^{1

3}, Michael Yong¹, Jayakar Nayak¹, Zara Patel¹, Peter H Hwang¹

Affiliations

¹ Division of Rhinology-Sinus and Skull Base Surgery, Department of Otolaryngology-Head and Neck Surgery, Stanford University School of Medicine, Stanford, California, USA.
² Ear, Nose and Throat Center, Park Ridge, Illinois, USA.
³ Department of Head and Neck Surgery, University of California Los Angeles, Los Angeles, California, USA.

PMID: 38297486
DOI: 10.1002/alr.23325

Abstract

Increased dupilumab utilization coincided with decreased ESS in patients with CRSwNP between 2019 and 2021. One potential confounder was the concurrent COVID-19 pandemic, which may have negatively impacted surgery utilization rates.

Keywords: FESS; chronic rhinosinusitis; endoscopic sinus surgery; eosinophilic rhinitis and nasal polyposis; medical therapy of chronic rhinosinusitis; therapeutics.

PubMed Disclaimer

Cited by

The use of biologics in patients suffering from chronic rhinosinusitis with nasal polyps - a 4-year real life observation.
Frankenberger H, Wiebringhaus R, Paul B, Huber P, Haubner F, Gröger M, Stihl C. Frankenberger H, et al. Eur Arch Otorhinolaryngol. 2024 Nov;281(11):5773-5782. doi: 10.1007/s00405-024-08790-y. Epub 2024 Jul 8. Eur Arch Otorhinolaryngol. 2024. PMID: 38977481 Free PMC article.
Impact of Biologics on Surgery in Chronic Rhinosinusitis with Polyps and Allergic Fungal Sinusitis.
Bentan MA, Pingree G, Lee L, Fitzpatrick T, Schuman T. Bentan MA, et al. Laryngoscope. 2025 Feb;135(2):593-601. doi: 10.1002/lary.31774. Epub 2024 Sep 17. Laryngoscope. 2025. PMID: 39290040 Free PMC article.

References

REFERENCES

1. Orlandi RR, Kingdom TT, Smith TL, Bleier B, DeConde A, Luong AU, eds. International Consensus Statement on Allergy and Rhinology: Rhinosinusitis 2021. International Forum of Allergy & Rhinology; 2021.
1. Benninger MS, Ferguson BJ, Hadley JA, et al. Adult chronic rhinosinusitis: definitions, diagnosis, epidemiology, and pathophysiology. Otolaryngol Head Neck Surg. 2003;129(3):S1‐S32.
1. Laidlaw TM, Mullol J, Fan C, et al. Dupilumab improves nasal polyp burden and asthma control in patients with CRSwNP and AERD. Allergy Clin Immunol Prac. 2019;7(7):2462‐2465.e1.
1. Bachert C, Han JK, Desrosiers M, et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS‐24 and LIBERTY NP SINUS‐52): results from two multicentre, randomised, double‐blind, placebo‐controlled, parallel‐group phase 3 trials. Lancet North Am Ed. 2019;394(10209):1638‐1650.
1. Fokkens WJ, Lund V, Bachert C, et al. EUFOREA consensus on biologics for CRSwNP with or without asthma. Allergy. 2019;74(12):2312‐2319.

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

Grants and funding

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Wiley
Medical
- MedlinePlus Health Information

[1] Orlandi RR, Kingdom TT, Smith TL, Bleier B, DeConde A, Luong AU, eds. International Consensus Statement on Allergy and Rhinology: Rhinosinusitis 2021. International Forum of Allergy & Rhinology; 2021.

[2] Orlandi RR, Kingdom TT, Smith TL, Bleier B, DeConde A, Luong AU, eds. International Consensus Statement on Allergy and Rhinology: Rhinosinusitis 2021. International Forum of Allergy & Rhinology; 2021.

[3] Benninger MS, Ferguson BJ, Hadley JA, et al. Adult chronic rhinosinusitis: definitions, diagnosis, epidemiology, and pathophysiology. Otolaryngol Head Neck Surg. 2003;129(3):S1‐S32.

[4] Benninger MS, Ferguson BJ, Hadley JA, et al. Adult chronic rhinosinusitis: definitions, diagnosis, epidemiology, and pathophysiology. Otolaryngol Head Neck Surg. 2003;129(3):S1‐S32.

[5] Laidlaw TM, Mullol J, Fan C, et al. Dupilumab improves nasal polyp burden and asthma control in patients with CRSwNP and AERD. Allergy Clin Immunol Prac. 2019;7(7):2462‐2465.e1.

[6] Laidlaw TM, Mullol J, Fan C, et al. Dupilumab improves nasal polyp burden and asthma control in patients with CRSwNP and AERD. Allergy Clin Immunol Prac. 2019;7(7):2462‐2465.e1.

[7] Bachert C, Han JK, Desrosiers M, et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS‐24 and LIBERTY NP SINUS‐52): results from two multicentre, randomised, double‐blind, placebo‐controlled, parallel‐group phase 3 trials. Lancet North Am Ed. 2019;394(10209):1638‐1650.

[8] Bachert C, Han JK, Desrosiers M, et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS‐24 and LIBERTY NP SINUS‐52): results from two multicentre, randomised, double‐blind, placebo‐controlled, parallel‐group phase 3 trials. Lancet North Am Ed. 2019;394(10209):1638‐1650.

[9] Fokkens WJ, Lund V, Bachert C, et al. EUFOREA consensus on biologics for CRSwNP with or without asthma. Allergy. 2019;74(12):2312‐2319.

[10] Fokkens WJ, Lund V, Bachert C, et al. EUFOREA consensus on biologics for CRSwNP with or without asthma. Allergy. 2019;74(12):2312‐2319.

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Impact of dupilumab prescribing on utilization of medical and surgical therapies for chronic rhinosinusitis with nasal polyps

Affiliations

Impact of dupilumab prescribing on utilization of medical and surgical therapies for chronic rhinosinusitis with nasal polyps

Authors

Affiliations

Abstract

Similar articles

Cited by

References

REFERENCES

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Medical

Abstract

Similar articles

Cited by

References

REFERENCES

MeSH terms

Substances

Related information

Grants and funding

LinkOut - more resources

Full Text Sources

Medical